Clinical Trials
19 trialsNCT01814501 2025-02-05
Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT03992456 2024-05-21
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Unknown
NCT00819780 2022-12-06
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
Amgen
Phase 2 Completed
NCT03000374 2022-03-17
PIER
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase 2 Completed
NCT00655499 2021-09-21
PIMABI
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Completed
NCT00940316 2019-05-07
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
Northwestern University
Phase 2 Completed
NCT00418938 2018-10-17
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
Amgen
Phase 2 Completed
NCT00973193 2016-04-20
PrePaRad
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Terminated
NCT00332163 2016-02-23
STEPP
Amgen
Phase 2 Completed
NCT00411450 2016-02-15
PRECEPT
Amgen
Phase 2 Completed
NCT01257360 2016-01-13
NEO-RIT
WiSP Wissenschaftlicher Service Pharma GmbH
Phase 2 Unknown
NCT01443377 2015-05-07
NEOREC-1
National Center for Tumor Diseases, Heidelberg
Phase 2 Completed
NCT00814619 2014-04-30
Capecitabine and Radiation Therapy With or Without Panitumumab in Treating Patients With Advanced Rectal Cancer
Swiss Cancer Institute
Phase 2 Completed
NCT00967655 2014-01-10
Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01110785 2013-09-17
Simvastatin and Panitumumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00111774 2013-05-14
Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma
Amgen
Phase 2 Completed
NCT00039273 2013-01-08
Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00113776 2011-01-21
Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer
Amgen
Phase 2 Completed
NCT00346099 2008-01-07
Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum
NSABP Foundation Inc
Phase 2 Withdrawn